T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the
development of innovative diagnostic products to improve patient
health, today announced a panel presentation and six poster
presentations during the IDWeek 2017 Conference in San Diego, CA,
held October 4-8. The panel presentation will be focused on the
positive impact of the T2Candida Panel, early experiences with the
T2Bacteria Research Use Only (RUO) Panel and how the development of
a diagnostic panel to detect Gram-negative bacterial species and
antibiotic resistance should impact antimicrobial stewardship.
Attendees are invited to visit T2 Biosystems at Booth #311
throughout the IDWeek Conference, where the Company will offer live
demonstrations of their diagnostic capabilities at the booth.
“We are excited for IDWeek attendees to learn more about T2
Biosystems’ full line of diagnostic products and capabilities,”
said John McDonough, president and chief executive
officer. “Through a range of abstracts and presentations
during the show, we will be sharing customer experiences with the
T2Sepsis Solution, including the T2Bacteria RUO Panel.”
A schedule of relevant presentations is as follows:
PANEL
PRESENTATION: TITLE: T2Sepsis
Solution: The Impact of Direct from Whole Blood Diagnostics on the
Management of Bloodstream Infections (T2Candida and the T2Bacteria
RUO Panel)Presenters:
- Cornelius J. Clancy, M.D., Associate Professor of Medicine,
Director, Mycology Program - University of Pittsburgh, Chief,
Infectious Diseases Section - VA Pittsburgh Healthcare System
- Glen T. Hansen, Ph.D., Director of Clinical Microbiology and
Molecular Diagnostics - Hennepin County Medical Center,
Minneapolis, MN
- Urania Rappo, M.D., Ph.D., Director, Medical and Clinical
Affairs, Allergan;
- Rahul Dhanda, Senior Vice President, Marketing & Business
Development, T2 Biosystems
Overview: The panel will share their
experiences using the T2Sepsis Solution, a unique approach that
combines the standard of care in the management of sepsis patients
with T2 Biosystems' tests that identify sepsis-causing pathogens
without blood culture in 3 to 5 hours with a sensitivity and
specificity of over 90%. Speakers will highlight how the
FDA-cleared T2Candida Panel is delivering significant improvements
in patient care, share early experiences with the T2Bacteria RUO
Panel, and discuss how the development of a diagnostic panel to
detect Gram-negative bacterial species and antibiotic resistance
will likely impact antimicrobial
stewardship. Time: October 4th, 7:00-8:00
a.m. PDTLocation: San Diego Convention Center,
Room 9
POSTER
PRESENTATIONS:TITLE: Detecting
Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A
Prospective, Multicenter Study of the T2Candida
PanelSession Title: Oral Abstract Session:
The Fungus Among-us – Clinical AdvancesPoster
Number: #1774Presenter: Cornelius J.
Clancy, M.D., Associate Professor of Medicine, Director, Mycology
Program - University of Pittsburgh, Chief, Infectious Diseases
Section - VA Pittsburgh Healthcare SystemTime:
October 7th, 8:30 a.m. PDTLocation: Room
01AB
TITLE: Utilization of the T2Candida Panel
for Rapid Candida Species Detection in a Large Community
HospitalSession Title: Poster Abstract
Session: Diagnostics - MycologyPoster Number:
#2066Presenter: Mohammed Abdulhaleem, M.D.,
Internal Medicine, UAB-Huntsville campusTime:
October 7th, 12:30-2:00 p.m. PDTLocation: Poster
Hall CD
TITLE: Relationship of T2Candida Panel to
Disease Severity, Mortality and Time to Therapy in Patients with
CandidemiaSession Title: Poster Abstract
Session: Diagnostic - MycologyPoster Number:
#2067Presenter: Orlando D. Turner, M.D., Division
of Infectious Diseases, University of Alabama at
BirminghamTime: October 7th, 12:30 PM-2:00 p.m.
PDTLocation: Poster Hall CD
TITLE: Automated Detection of Candida
auris Direct from Whole Blood by T2MRSession
Title: Poster Abstract Session: Diagnostics -
MycologyPoster Number:
#2069Presenter: T2
BiosystemsTime: October 7th, 12:30-2:00 p.m.
PDTLocation: Poster Hall CD
TITLE: Does a Negative Rapid Diagnostic
Test for Detection of Candida Bloodstream Infection Lead to Less
Antifungal Use?Session Title: Poster
Abstract Session: Diagnostics - MycologyPoster
Number: #2081Presenter: Tanya Bhowmick,
M.D., Rutgers Robert Wood Johnson Medical
SchoolTime: October 7th, 12:30-2:00 p.m.
PDTLocation: Poster Hall CD
TITLE: Influence of T2Candida Testing for
Rapid Diagnosis of Candida Infections on Antifungal Stewardship
Efforts at a Large Academic Medical Center: A Retrospective,
Single-Center StudySession Title: Poster
Abstract Session: Stewardship: Impact of DiagnosticsPoster
Number: #2137Presenter: Justin F. Hayes,
M.D., Division of Infectious Diseases, University of Alabama at
BirminghamTime: October 7th, 12:30-2:00 p.m.
PDTLocation: Poster Hall CD
About T2 Biosystems T2 Biosystems, an emerging
leader in the field of in vitro diagnostics, is dedicated to saving
lives and reducing the cost of healthcare by empowering clinicians
to effectively treat patients faster than ever before. T2
Biosystems is focused on addressing critical unmet needs in
healthcare starting with sepsis, one of the deadliest and most
expensive conditions in hospitals today. The T2Sepsis SolutionTM is
a unique approach that combines the standard of care for the
management of sepsis patients with T2 Biosystems’ products,
including the T2Dx® Instrument and T2Candida® Panel, and the
T2Bacteria® Panel, which is commercially available in Europe and
other countries that accept the CE mark and available for research
use only in the U.S. Powered by the proprietary T2 Magnetic
Resonance technology, or T2MR®, the T2Sepsis Solution is proven to
deliver better patient care and greater cost savings. Hospital
customer experience has demonstrated faster time to effective
treatment, shortened ICU and hospital lengths of stay, reduced use
of unnecessary antifungals, and millions of dollars in savings. T2
Biosystems has an active pipeline of future sepsis products
including additional species and antibiotic resistance, as well as
tests for Lyme disease and hemostasis. For more information, please
visit www.t2biosystems.com.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements, including, without limitation, statements regarding ,
product pipeline, anticipated product benefits, goals and strategic
priorities, product expansion or opportunities, growth expectations
or targets and FDA clearance, as well as statements that
include the words “expect,” “intend,” “plan,” “believe,” “project,”
“forecast,” “estimate,” “may,” “should,” “anticipate” and similar
statements of a future or forward-looking nature. These
forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, (i) any
inability to (a) realize anticipated benefits from commitments,
contracts or products; (b) successfully execute strategic
priorities; (c) bring products to market; (d) expand product usage
or adoption; (e) obtain customer testimonials; (f) accurately
predict growth assumptions; (g) realize anticipated revenues; (h)
incur expected levels of operating expenses; or (i) increase the
number of high-risk patients at customer facilities; (ii) failure
of early data to predict eventual outcomes; (iii) failure to
make or obtain anticipated FDA filings or clearances within
expected time frames or at all; or (iv) the factors discussed under
Item 1A. "Risk Factors" in the company's Annual Report on Form 10-K
for the year ended December 31, 2016, filed with the U.S.
Securities and Exchange Commission, or SEC, on March 15, 2017, and
other filings the company makes with the SEC from time to
time. These and other important factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While the company may elect to
update such forward-looking statements at some point in the future,
unless required by law, it disclaims any obligation to do so, even
if subsequent events cause its views to change. Thus, one should
not assume that the Company’s silence over time means that actual
events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements should
not be relied upon as representing the company's views as of any
date subsequent to the date of this press release.
Company Contact:Darlene Deptula-Hicks, T2
BiosystemsSVP & Chief Financial
Officerddeptula@t2biosystems.com603-553-5803
Media Contact:Amy Phillips, Feinstein Kean
Healthcareamy.phillips@fkhealth.com412-327-9499
Investor Contact:Chris Brinzey, Westwicke
Partners chris.brinzey@westwicke.com339-970-2843
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024